secwatch.observer — SEC 8-K summary
======================================

Issuer:     Hoth Therapeutics, Inc. (HOTH)
CIK:        0001711786
Form:       8-K
Filed at:   2025-10-17T23:59:59+00:00
Accession:  0001213900-25-099969
Event type: other_material
Sentiment:  neutral
Materiality: 0.30
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Hoth Therapeutics updates corporate presentation with clinical milestones and cash position
--------------------------------------------------------------------------------

- HT-001 Phase 2a open-label cohort showed promising results; case study published Sept 2024.
- HT-KIT IND-enabling tox studies initiated Q1 2024; target IND submission Q4 2026.
- HT-ALZ patent awarded Q3 2024; preclinical studies at Washington University completed.
- HT-VA license from Veteran's Affairs obtained Q1 2025; CRADA executed Q2 2025.
- 15.4M shares outstanding as of Oct 14, 2025; cash sufficient for clinical and preclinical programs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1711786/000121390025099969/0001213900-25-099969-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1711786/000121390025099969/ea0261354-8k_hoth.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-099969

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer